If You Invested $10,000 in Arcturus in January, This Is How Much You'd Have Now
This might be the year for mRNA drugs. The most prominent name in this space, Moderna, is up a fantastic 700% in 2020. And returns for BioNTech haven't been too shabby with its stock quadrupling in a year. While those investors certainly aren't complaining, the biggest mRNA winner is actually tiny Arcturus Therapeutics (NASDAQ: ARCT) -- $10,000 could have bought you 1,000 shares of Arcturus on Jan. 2. That position would be worth a cool $105,000 as of this writing.
Why is the market in love with these mRNA pharmaceutical stocks? The race to find a COVID-19 vaccine gives us an answer. What people call "the Pfizer drug" is actually the BioNTech drug, as it was the smaller biotech that actually found the molecule. The two front runners in the vaccine race right now are both mRNA drugs.
Image source: Getty Images
Source Fool.com
